[go: up one dir, main page]

CN103102407A - Genetic recombinant human-like collagen - Google Patents

Genetic recombinant human-like collagen Download PDF

Info

Publication number
CN103102407A
CN103102407A CN2013100332996A CN201310033299A CN103102407A CN 103102407 A CN103102407 A CN 103102407A CN 2013100332996 A CN2013100332996 A CN 2013100332996A CN 201310033299 A CN201310033299 A CN 201310033299A CN 103102407 A CN103102407 A CN 103102407A
Authority
CN
China
Prior art keywords
collagen
gly
col3
pro
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2013100332996A
Other languages
Chinese (zh)
Other versions
CN103102407B (en
Inventor
梁亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Chuangjian Medical Technology Co ltd
Original Assignee
XI'AN ELAGEN BIOLOGICAL TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XI'AN ELAGEN BIOLOGICAL TECHNOLOGY Co Ltd filed Critical XI'AN ELAGEN BIOLOGICAL TECHNOLOGY Co Ltd
Priority to CN201310033299.6A priority Critical patent/CN103102407B/en
Publication of CN103102407A publication Critical patent/CN103102407A/en
Application granted granted Critical
Publication of CN103102407B publication Critical patent/CN103102407B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention discloses humanized genetic recombinant human-like collagen produced by eukaryotic bacteria. The humanized genetic recombinant human-like collagen has amino acid with the total length of 474, and is formed by connecting two sections of completely-identical human III-type collagen sections in series; the end C is connected with six histidine residue groups serving as specificity affinity purification markers. The performance of the genetic recombination human-like collagen is superior to animal collagens and original nuclear engineering bacteria recombinant collagens; and with the specificity affinity purification markers, the high-purity product is easily acquired.

Description

Gene recombination human collagen
Technical field
The invention belongs to gene engineering technology field, be specifically related to a kind of recombined collagen and production method thereof.
Background technology
Collagen protein is a kind of Basic knowledge of analytical reagents, is form and the structure of keeping skin and histoorgan, is also the important substance of repairing each damaged tissue.Mainly being present in skin, bone, cartilage, tooth, tendon, ligament and the blood vessel of humans and animals, is structural protein important in reticular tissue, plays the function that supports organ, protection body.Collagen protein plays an important role to normal physiological function and the injury repairing of safeguarding cell, tissue, organ.Collagen protein can contain the necessary nutrient of skin layer of collagen protein, make active reinforcement of collagen protein in skin, the integrity that keeps stratum corneum moisture and fibrous texture, improve the metabolism of skin cells living environment and promotion skin histology, increase circulation, reach the skin care delaying retrogradation, beauty treatment, wrinkle-chasing, the purpose of hair care.
The traditional method of producing collagen protein is to utilize acid, alkali or enzyme to process animal tissues's (pigskin, ox-hide, donkey hide, fish-skin/squama etc.), therefrom extracts collagen protein.Although these methods are with low cost, the rate of recovery is higher, the collagen protein of producing is the mixing collagen peptide section that molecular weight is very little and length does not wait, and is commonly called as gelatin, is difficult to play the effect of moisturizing, nourishing; Extraction process is simply extensive, and product purity is not good, and peculiar smell is often arranged; Animal-origin can't be broken away from Biosafety hidden danger, has limited greatly the widespread use of traditional collagen in the various products such as makeup, food, medicine; When extracting, processing produces flood tide waste water grievous injury environment; Technology door mulberry is low, and raw material sources are wayward, causes leather shoes milk, toxic capsule to walk crosswise, and food, drug safety hidden danger are serious.
In order to explain the series of problems of traditional animal collagen, many scholars take up Applied Biotechnology and produce recombinant collagen, and because of all facilities of microorganism culturing, utilizing recombinant microorganism to produce collagen becomes main flow gradually.Industrialization is produced, and use the intestinal bacteria high density fermentation as Fan Daidi and cultivate the recombination human collagen of producing, and successful Application arrives cosmetic field.But the bacterial expression system has the Biosafety problems such as intracellular toxin, pyrogen, makes the high enterprise of production, testing cost of product, and has hidden danger; The albumen of expressing exists in bacterial cell with the inclusion body form, and product purification is difficult, the rate of recovery is restricted; Prokaryotic expression system is more rudimentary in addition, can not complete the translation post-treatment of expression product and modify, and makes product not have biological activity.
Therefore, increasing scholar begins to utilize eukaryotic microorganisms Restruction collagen: Zhang Fenglong etc. to utilize synthetic almost completely humanized's the recombinant collagen of pichia spp, is applied to makeup.But its purification process has only adopted traditional nonspecific macromole isolation technique such as ultrafiltration, gel-filtration, ion-exchange, purity is not high enough, foreign protein and Partial digestion albumen can't be thorough degree remove, can not meet Wicresoft's beauty treatment, shaping and beauty to the requirements at the higher level of purity.
Summary of the invention
Technical problem to be solved by this invention is the deficiency for above-mentioned existing recombinant collagen and technology of preparing thereof, and a kind of recombinant collagen of full-length human of eucaryon engineering bacteria production is provided, and its performance is much better than animal collagen, prokaryotic micro-organisms recombinant collagen; With specificity affinity purification mark, be easy to obtain high purity product simultaneously.
474 amino acid of gene recombination human collagen total length are in series by two sections identical human III type collagen fragment, and C-terminal connects 6 histidine residues, and (SEQ ID NO.1) is as follows for its sequence:
AGNTGAPGSP GVSGPKGDAG QPGEKGSPGA QGPPGAPGPL GIAGITGARG 50 LAGPPGMPGP RGSPGPQGVK GESGKPGANG LSGERGPPGP QGLPGLAGTA 100 GEPGRDGNPG SDGLPGRDGS PGGKGDRGEN GSPGAPGAPG HPGPPGPVGP 150 AGKSGDRGES GPAGPAGAPG PAGSRGAPGP QGPRGDKGET GERGAAGIKG 200 HRGFPGNPGA PGSPGPAGQQ GAIGSPGPAE FTAGNTGAPG SPGVSGPKGD 250 AGQPGEKGSP GAQGPPGAPG PLGIAGITGA RGLAGPPGMP GPRGSPGPQG 300
VKGESGKPGA NGLSGERGPP GPQGLPGLAG TAGEPGRDGN PGSDGLPGRD 350 GSPGGKGDRG ENGSPGAPGA PGHPGPPGPV GPAGKSGDRG ESGPAGPAGA 400 PGPAGSRGAP GPQGPRGDKG ETGERGAAGI KGHRGFPGNP GAPGSPGPAG  450 QQGAIGSPGP ADHHHHHHTG LARF    474
Albumen is single-stranded structure, wherein 1~229 and 233~461 is identical III Collagen Type VI peptide section, there is EFT to connect between two sections human III type collagen segments, adopt DHHHHHHTGLARF to modify after 233~461 the former fragment of human III type glue protein, wherein 463~468 is affinity purification mark 6His.
Gene recombination engineering bacteria and the protein preparation method of producing above-mentioned albumen are comprised of following step:
(1), the structure of recombinant expression vector
Extract total RNA from people's fresh human placenta, reverse transcription is cDNA, according to GenBank III type human collagen COL3A1 gene order, design pcr amplification primer F(SEQ ID NO.2), R(SEQ ID NO.3):
F: GAATCTGTGAATCATGCCCTAC
R: GAAGTCATAATCTCATCGGTGTT
Take cDNA as masterplate pcr amplification COL3A1 gene, product length is 3295bp.Reclaim the specificity product and be connected in the pGM-T carrier, obtain plasmid pGM-T-COL3A1;
According to the method for multiplex PCR in " molecular cloning experiment guide ", take pGM-T-COL3A1 plasmid as template, use primers F 1, F2, R to carry out the multiplex PCR amplification, obtain the product C OL3 that product is 722bp, primer is:
(SEQ ID NO.4)F1:AGGCTGAAGCTGCGGGTAACACTG
(SEQ ID NO.5)F2:TCTCTCGAGAAAAGAGAGGCTGAAGCT
(SEQ ID NO.6)R: TTGAATTCTGCAGGTCCTGG
Product C OL3 and carrier pPIC9K are done respectively EcoR I, Xho I double digestion, and be connected to become pPIC9K-COL3 through the T4 DNA ligase;
Take plasmid pPIC9K-COL3 as template, the design primer, the COL3 that again increases adds the 6His mark simultaneously.Primer is:
(SEQ ID NO.7)F:CCCGAATTCACTGCGGGTAACACTGGTGC
(SEQ ID NO.8)R:AAAACCGGTGTGGTGGTGGTGGTGGTGATCTGCAGGTCCTGGACTG
Secondary amplified production COL3-6His and plasmid pPIC9K-COL3 are carried out respectively EcoR I, Age I double digestion, and be connected to become pPIC9K-COL3-COL3-6His through the T4 DNA ligase.The gene order of target protein is as follows:
1 GCGGGTAACA CTGGTGCTCC TGGCAGCCCT GGAGTGTCTG GACCAAAAGG
51 TGATGCTGGC CAACCAGGAG AGAAGGGATC GCCTGGTGCC CAGGGCCCAC
101 CAGGAGCTCC AGGCCCACTT GGGATTGCTG GGATCACTGG AGCACGGGGT
151 CTTGCAGGAC CACCAGGCAT GCCAGGTCCT AGGGGAAGCC CTGGCCCTCA
201 GGGTGTCAAG GGTGAAAGTG GGAAACCAGG AGCTAACGGT CTCAGTGGAG
251 AACGTGGTCC CCCTGGACCC CAGGGTCTTC CTGGTCTGGC TGGTACAGCT
301 GGTGAACCTG GAAGAGATGG AAACCCTGGA TCAGATGGTC TTCCAGGCCG
351 AGATGGATCT CCTGGTGGCA AGGGTGATCG TGGTGAAAAT GGCTCTCCTG
401 GTGCCCCTGG CGCTCCTGGT CATCCAGGCC CACCTGGTCC TGTCGGTCCA
451 GCTGGAAAGA GTGGTGACAG AGGAGAAAGT GGCCCTGCTG GCCCTGCTGG
501 TGCTCCCGGT CCTGCTGGTT CCCGAGGTGC TCCTGGTCCT CAAGGCCCAC
551 GTGGTGACAA AGGTGAAACA GGTGAACGTG GAGCTGCTGG CATCAAAGGA
601 CATCGAGGAT TCCCTGGTAA TCCAGGTGCC CCAGGTTCTC CAGGCCCTGC
651 TGGTCAGCAG GGTGCAATCG GCAGTCCAGG ACCTGCAGAA TTCACTGCGG
701 GTAACACTGG TGCTCCTGGC AGCCCTGGAG TGTCTGGACC AAAAGGTGAT
751 GCTGGCCAAC CAGGAGAGAA GGGATCGCCT GGTGCCCAGG GCCCACCAGG
801 AGCTCCAGGC CCACTTGGGA TTGCTGGGAT CACTGGAGCA CGGGGTCTTG
851 CAGGACCACC AGGCATGCCA GGTCCTAGGG GAAGCCCTGG CCCTCAGGGT
901 GTCAAGGGTG AAAGTGGGAA ACCAGGAGCT AACGGTCTCA GTGGAGAACG
951 TGGTCCCCCT GGACCCCAGG GTCTTCCTGG TCTGGCTGGT ACAGCTGGTG
1001 AACCTGGAAG AGATGGAAAC CCTGGATCAG ATGGTCTTCC AGGCCGAGAT
1051  GGATCTCCTG GTGGCAAGGG TGATCGTGGT GAAAATGGCT CTCCTGGTGC
1101  CCCTGGCGCT CCTGGTCATC CAGGCCCACC TGGTCCTGTC GGTCCAGCTG
1151  GAAAGAGTGG TGACAGAGGA GAAAGTGGCC CTGCTGGCCC TGCTGGTGCT
1201  CCCGGTCCTG CTGGTTCCCG AGGTGCTCCT GGTCCTCAAG GCCCACGTGG
1251  TGACAAAGGT GAAACAGGTG AACGTGGAGC TGCTGGCATC AAAGGACATC
1301  GAGGATTCCC TGGTAATCCA GGTGCCCCAG GTTCTCCAGG CCCTGCTGGT
1351  CAGCAGGGTG CAATCGGCAG TCCAGGACCT GCAGATCACC ACCACCACCA
1401  CCACACCGGT CTTGCTAGAT TC           (SEQ ID NO.9)。
(2) structure of gene recombination engineering bacteria pichia spp
With the pPIC9K-COL3-COL3-6His restriction enzyme for preparing SalI linearizing, and preparation pichia spp SMD1168(Invitrogen) competent cell, electric shock transforms the pPIC9K-COL3-COL3-6His plasmid.Select high copy positive colony with the G418 gradient method, obtain pichia yeast genetic engineering bacteria and (be preserved in China Committee for Culture Collection of Microorganisms's common micro-organisms center, deposit number CGMCC NO. 7189, preservation date: on January 21st, 2013, the address: No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, Classification And Nomenclature: pasteur is than red yeast Pichia pastoris).
(3) preparation gene recombination human collagen
Cultivate based on 30 ℃ of 250rpm with BMGY and cultivated pichia yeast genetic engineering bacteria 16 ~ 18 hours, OD 600=2~6; The centrifugal 5min of 1500g~3000g under room temperature collects thalline, with the resuspended thalline of BMMY substratum, makes OD 600=1.0 left and right are placed in the bacterium liquid of gained the triangular flask of 500mL, with the double gauze sealing, in 30 ℃ of 250rpm continued growths; Adding methyl alcohol to final concentration in every 24 hours in the substratum is 1% beginning inducing culture, until more than 100 hours.After fermentation culture finishes, centrifugal collection supernatant, with Ni-NTA His Bands resin (Merck) absorption recombinant collagen, rinse streams goes out impurity under non-Denaturing, and wash-out recombinant collagen again, collect elutriant at last.Elutriant is through ultrafiltration system (PALL) desalination, concentrated.Concentrated solution obtained by freeze drying gene recombination human collagen.
As the functional raw material of makeup, the using method of gene recombination human collagen in makeup is described as follows:
Take the gene recombination human collagen lyophilized powder, add 5% N.F,USP MANNITOL in the 1mg:1mL ratio, fully after dissolving, filtration sterilization, under aseptic condition, every 1mL packing pours in the aseptic cillin bottle of 3mL, partly covers aseptic plug, after vacuum lyophilization, roll aluminium lid, make gene recombination human collagen and import lyophilized powder.Another preparation 0.05% hyaluronic acid solution, filtration sterilization is filled under aseptic condition in the aseptic cillin bottle of 3mL, covers aseptic plug, rolls aluminium lid, makes the lyophilized powder solvent.When the beauty salon uses, with the whole solvents of disposable sterilized injector extraction, inject the freeze-drying powder bottle, shake up and make abundant dissolving, and then the cooperation of extraction solution imports the instrument use.
The present invention compared with prior art has the following advantages:
1. traditional collagen of comparing, the immunological rejection that the gene recombination human collagen of full-length human has avoided animal collagen to bring has been stopped Biosafety hidden danger, and technological process is environmentally friendly;
2. the existing collagen from the protokaryon engineering bacteria of comparing, gene recombination human collagen is without intracellular toxin hidden danger;
3. the existing collagen from the eucaryon engineering bacteria of comparing, gene recombination human collagen carries specificity affinity purification mark, and purification step is simple, and product purity is very high, satisfies Wicresoft, the shaping and beauty product uses.
Description of drawings
Fig. 1 is carrier pPIC9K-COL3-COL3-6His constructing technology route map.
Fig. 2 is the electrophorogram of restructured Pichia pastoris in expression gene recombination human collagen.
Embodiment
Embodiment 1
474 amino acid of gene recombination human collagen total length are in series by two sections identical human III type collagen fragment, and end connects 6 histidine residues, and (SEQ ID NO.1) is as follows for its sequence:
AGNTGAPGSP GVSGPKGDAG QPGEKGSPGA QGPPGAPGPL GIAGITGARG 50 LAGPPGMPGP RGSPGPQGVK GESGKPGANG LSGERGPPGP QGLPGLAGTA 100 GEPGRDGNPG SDGLPGRDGS PGGKGDRGEN GSPGAPGAPG HPGPPGPVGP 150 AGKSGDRGES GPAGPAGAPG PAGSRGAPGP QGPRGDKGET GERGAAGIKG 200 HRGFPGNPGA PGSPGPAGQQ GAIGSPGPAE FTAGNTGAPG SPGVSGPKGD 250 AGQPGEKGSP GAQGPPGAPG PLGIAGITGA RGLAGPPGMP GPRGSPGPQG 300
VKGESGKPGA NGLSGERGPP GPQGLPGLAG TAGEPGRDGN PGSDGLPGRD 350 GSPGGKGDRG ENGSPGAPGA PGHPGPPGPV GPAGKSGDRG ESGPAGPAGA 400 PGPAGSRGAP GPQGPRGDKG ETGERGAAGI KGHRGFPGNP GAPGSPGPAG  450 QQGAIGSPGP ADHHHHHHTG LARF    474
Albumen is single-stranded structure, wherein 1~229 and 233~461 is identical III Collagen Type VI peptide section, there is EFT to connect between two sections human III type collagen segments, adopt DHHHHHHTGLARF to modify after 233~461 the former fragment of human III type glue protein, wherein 463~468 is affinity purification mark 6His.
The preparation method is as follows:
1. the structure of recombinant expression vector
1.1. RNA extracts (with reference to the TaKaRa RNAiso Plus of company reagent specification sheets)
(1) take people's fresh human placenta of freezing through very low temperature and organize approximately 50mg, be transferred to rapidly with in the mortar of Liquid nitrogen precooler, use pestle tissue abrasion, constantly add liquid nitrogen therebetween, until be ground into powder;
(2) add appropriate RNAiso Plus in mortar, pulverous sample is covered fully, then room temperature is standing, until sample melts fully, then continues to be ground to lysate with pestle and is transparence;
(3) homogenate is transferred in centrifuge tube standing 5 minutes of room temperature;
(4) centrifugal 5 minutes of 4 ℃ of 12,000g;
(5) draw supernatant liquor, move in new centrifuge tube;
(6) add chloroform (1/5 volume of RNAiso Plus), cover tightly the centrifuge tube lid, thermal agitation 15 seconds.After solution is fully emulsified, more standing 5 minutes of room temperature;
(7) centrifugal 15 minutes of 4 ℃ of 12,000g.Drawing supernatant liquor is transferred in another new centrifuge tube;
(8) add isopyknic Virahol, after the abundant mixing of the centrifuge tube that turns upside down, under 15~30 ℃ standing 10 minutes;
(9) centrifugal 10 minutes of 4 ℃ of 12,000g;
(10) careful supernatant discarded adds 75% ethanol lml lentamente along centrifugal tube wall, the washing centrifuge tube tube wall that turns upside down gently, and 4 ℃ of 12,000g carefully discard ethanol after centrifugal 5 minutes;
(11) the drying at room temperature precipitation is 2~5 minutes, adds appropriate RNase-free water dissolution precipitation, and dissolving is rear in-80 ℃ of preservations fully.
1.2. reverse transcription (with reference to the TaKaRa PrimeScript RT-PCR Kit of company specification sheets)
(1) the following mixed solution of preparation in the Microtube pipe:
Using amount of reagent
dNTP Mixture(10 mM each) 1μL
Random 6 mers(20 μM) 1μL
Template RNA 5μL
RNase Free dH2O supplies 10 μ L
(2) carry out sex change, annealing reaction on the PCR instrument: 65 ℃ of 5min, cooled on ice;
(3) the centrifugal several seconds makes the mixed solution of template ribonucleic acid/primer etc. be gathered in Microtube pipe bottom;
(4) the following inverse transcription reaction liquid of preparation in above-mentioned Microtube pipe:
Using amount of reagent
Above-mentioned sex change, annealing afterreaction liquid 10 μ L
5×PrimeScript Buffer 4μL
RNase Inhibitor(40 U/μL) 0.5μL
PrimeScript RTase 0.5 μL
RNase Free dH2O 5 μL
(5) carry out reverse transcription reaction by following condition on the PCR instrument: 30 ℃ of 10min, 42 ℃ of 30min, 70 ℃ of 10min, cooled on ice.
1.3. amplification COL3A1 gene (with reference to the TaKaRa PrimeScript RT-PCR Kit of company specification sheets)
According to GenBank III type human collagen COL3A1 gene order, design pcr amplification primer F, R:
F: GAATCTGTGA ATCATGCCCT AC (SEQ ID NO.2)
R: GAAGTCATAA TCTCATCGGT GTT (SEQ ID NO.3)
Prepare the PCR reaction solution by following composition:
Using amount of reagent
10×PCR Buffer Ⅱ 5μL
dNTP Mixture(10 mM each) 2μL
Primers F 0.5 μ L
Primer R 0.5 μ L
TaKaRa Ex Taq HS(5 U/μL) 0.5 μL
Above-mentioned inverse transcription reaction liquid≤5 μ L
RNase Free dH2O supplies 50 μ L
Reaction conditions is respectively: 95 ℃ of 5min---(94 ℃ of 30S---60 ℃ of 30S---72 ℃ of 2.5min) 4 ℃ of 10min of 30cycles---72 ℃ of 10min---.
1.4. preparation pGMT-COL3A1 plasmid
Utilize sepharose DNA to reclaim test kit (the TaKaRa Agarose Gel DNA Fragment Recovery Kit of company), press product description, reclaim the specific band COL3A1 of 3295bp from 1.5% common sepharose.By the biochemical pGM-T clone of day root test kit specification sheets, connect COL3A1 on the pGM-T carrier, transformed competence colibacillus E.coli DH 5 α, spread plate through blue hickie screening, is selected positive colony and is inoculated in 10mL LB substratum, and 37 ℃ of shaken overnight are cultivated.Obtain plasmid pGM-T-COL3A1.
1.5. double digestion COL3
(1) according to the method for multiplex PCR in " molecular cloning experiment guide ", take the pGM-T-COL3A1 plasmid as template, use primers F 1, F2, R to carry out the multiplex PCR amplification, obtain the product C OL3 that product is 722bp, primer is:
(SEQ ID NO.4)F1:AGGCTGAAGCTGCGGGTAACACTG
(SEQ ID NO.5)F2:TCTCTCGAGAAAAGAGAGGCTGAAGCT
(SEQ ID NO.6)R: TTGAATTCTGCAGGTCCTGG
Reaction system is:
Using amount of reagent
10×Reaction Buffer 5μL
dNTP Mixture (10 mM each) 2.0μL
pGM-T-COL3A1 5μL
Each 0.5 μ L of Primer F1/F2 (20 μ M)
Primer R (20μM) 1μL
Taq enzyme 0.5 μ L
ddH 2O supplies 50 μ L
Reaction conditions is:
95℃ 5 min——(94℃ 30 S——60℃ 30 S——72℃ 40S)30 cycles-—72℃ 10 min
(2) utilize sepharose DNA to reclaim test kit (the TaKaRa Agarose Gel DNA Fragment Recovery Kit of company), press product description, reclaim the specific band COL3 of 722bp from 1.5% common sepharose;
(3) COL3 after the recovery carries out double digestion by 37 ℃ of water-baths digestion 1.5~2.0h of following system:
Using amount of reagent
10×buffer 20μL
COL3(150ng/μL) 40μL
EcoRⅠ 5μL
XhoⅠ 5μL
ddH 2O supplies 200 μ L
First take out 5 μ L before termination reaction and detect with 0.7% agarose gel electrophoresis whether enzyme cuts entirely;
(4) utilize sepharose DNA to reclaim test kit (the TaKaRa Agarose Gel DNA Fragment Recovery Kit of company), press product description, reclaim enzyme slitting band from 1.5% common sepharose ,-20 ℃ of preservations are stand-by.
1.6. build the pPIC9K-COL3 plasmid
(1) get freezing DH5 α competent cell one pipe, be put on ice and thaw, add immediately plasmid pPIC9K (<=50ng), finger flicks and makes its mixing, placed 30 minutes in ice;
Lucky 90 seconds of (2) 42 ℃ of water-bath heat shocks are transferred to pipe in ice bath fast, make cooling 1 – of cell 2 minutes;
(3) add the LB liquid nutrient medium of 800 μ L antibiotic-frees, mixing, 37 ℃ of incubations 50 minutes;
(4) draw 100-200 μ L bacterium liquid, be applied on the solid LB flat board that contains kantlex (50 μ g/mL);
(5) 37 ℃ of incubators are inverted and were cultivated 12-18 hour;
(6) select single colony inoculation in the liquid LB substratum that contains kantlex (50 μ g/mL), 37 ℃, 150rpm shaking table overnight incubation is utilized the plasmid extraction kit operation instructions afterwards, and the plasmid that carries out pPIC9K extracts in a large number;
(7) by a large amount of double digestion pPIC9K of following system:
Using amount of reagent
10×buffer 20μL
pPIC9K (200ng/μL) 35μL
XhoⅠ 5μL
EcoRⅠ 5μL
ddH 2O supplies 200 μ L
(8) press glue and reclaim test kit (the TaKaRa Agarose Gel DNA Fragment Recovery Kit of company), product description reclaims enzyme slitting band;
(9) mix by following system, the COL3 of double digestion is connected with pPIC9K connects 2 hours under 16 ℃:
Using amount of reagent
COL3(100 ng/μL) 11μL
pPIC9K (200ng/μL) 5μL
buffer 2μL
T4 DNA ligase 2 μ L
(10) connect product by a large amount of pPIC9K-COL3 plasmids of above-mentioned steps (1)~(6) preparation ,-20 ℃ of preservations are stand-by.
1.7. preparation COL3-6His
(1) take plasmid pPIC9K-COL3 as template, the design primer, the COL3 that again increases adds the 6His mark simultaneously.Primer is:
F:CCCGAATTCACTGCGGGTAACACTGGTGC(SEQ ID NO.7)
R:AAAACCGGTGTGGTGGTGGTGGTGGTGATCTGCAGGTCCTGGACTG(SEQ ID NO.8)
Reaction system is:
Using amount of reagent
10×Reaction Buffer 5μL
dNTP Mixture (10 mM each) 1.0μL
pPIC9K-COL3 1μL
Primer F (20μM) 1μL
Primer R (20μM) 1μL
Taq enzyme 1 μ L
ddH 2O supplies 50 μ L
Reaction conditions is:
94℃ 5 min——(94℃ 30 S——55℃ 30 S——72℃ 1min)30 cycles——72℃ 10 min
(2) utilize sepharose DNA to reclaim test kit (the TaKaRa Agarose Gel DNA Fragment Recovery Kit of company), press product description, reclaim specific band COL3-6His from sepharose.
1.8. preparation pPIC9K-COL3-COL3-6His plasmid
(1) COL3-6His and plasmid pPIC9K-COL3 are pressed respectively following system EcoRI and a large amount of double digestions of AgeI:
Using amount of reagent
10×buffer 20μL
COL3-6His or pPIC9K-COL3 (200ng/ μ L) 35 μ L
AgeI 5μL
EcoRⅠ 5μL
ddH 2O supplies 200 μ L
Reclaim the purpose fragment, be connected to become the pPIC9K-COL3-COL3-6His plasmid by following system:
Using amount of reagent
pPICK9-COL3 0.5μL
COL3-6His 5μL
Buffer 1μL
T4 ligase enzyme 0.5 μ L
ddH 2O supplies 10 μ L
(2) step by (1)~(6) in 1.6 prepares the pPIC9K-COL3-COL3-6His plasmid in a large number, and-20 ℃ of preservations are stand-by.
2. the structure of recombinant yeast pichia pastoris engineering bacteria
2.1. the linearizing of pPIC9K-COL3-COL3-6His plasmid
Get restriction enzyme SalI 10 μ L, about pPIC9K-COL3-COL3-6His plasmid 20 μ g, add 100 μ L buffer H, add water and supply mixing after 1000 μ L, 37 ℃ of water-bath digestion 5h first take out 5 μ L reaction solutions before termination reaction, detect with 0.7% agarose gel electrophoresis whether enzyme cuts entirely, enzyme carries out plasmid extraction with plasmid extraction kit to linearization plasmid after cutting entirely.
2.2. the preparation of pichia spp (SMD1168) competent cell
(1) picking yeast list bacterium colony is seeded to and contains in 5mL YPD substratum test tube, 30 ℃, 250rpm overnight incubation;
(2) culture of getting 50 μ L is seeded in the 300mL triangular flask that contains the 50mL fresh culture, and 28 ~ 30 ℃, 250rpm overnight incubation are to OD 600Value reaches 1.1-1.3;
(3) with culture in 4 ℃, the centrifugal 5min of 1500g, with the sterilized water of the ice precooling of 50mL, that bacterial sediment is resuspended;
(4) centrifugal by step (3), the sterilized water of the ice precooling of use 25mL is resuspended with bacterial sediment;
(5) centrifugal by step (3), the Sorbitol Solution USP of the 1mol/L of the ice precooling of use 20mL is resuspended with bacterial sediment;
(6) centrifugal by step (3), the Sorbitol Solution USP of the 1mol/L of the ice precooling of use 0.3mL is resuspended with bacterial sediment, and its final volume is about 0.5mL;
(7) every 80 μ L packing are a ,-70 ℃ of preservations.
2.3. the electricity of pichia spp transforms
(1) rinse electricity with dehydrated alcohol and transform cup three times, dry residual ethanol in the super clean bench of the bacterium of going out;
(2) electricity is transformed cup and went in ice precooling 10 minutes;
(3) the linearizing pPIC9K-COL3-COL3-6His plasmid with 5 ~ 20 μ g is dissolved in 5 ~ 10 μ L sterilization distilled waters, and with pichia spp competent cell mixing, the electricity that goes to the precooling of 0.2cm ice transforms in cup;
(4) electric shock, voltage 1.5kV; Electric capacity 25 μ F; Resistance 200 Ω; The electric shock time is 4 ~ 10mSec;
(5) electric shock complete after, add the Sorbitol Solution USP of 1mol/L of 1mL ice precooling with the thalline mixing, go in the 1.5mL centrifuge tube;
(6) the thalline suspension is coated on the MD flat board every 100 μ L ~ 200 μ L coating one flat plates.
2.4. multiple copied inserts the screening of recon
(1) there is the MD planar surface of transformant to add 2mL sterilization distilled water in growth, then is coated with gently on His+ transformant surface with aseptic triangle spreader and scrapes, and transfer in the 50mL centrifuge tube;
(2) add the dilution of 20mL sterilization distilled water, measure its OD600 value (1 OD600=5 * 10 after mixing 7Cells/mL);
(3) get 10 5Individual cell is coated on the YPD flat board that contains 0.5mg/mL G418, is inverted, and cultivates 72 ~ 96h for 30 ℃;
(4) every hole adds 200 μ L YPD liquid nutrient mediums in aseptic 96 orifice plates;
(5) access respectively the transformant that obtains on the YPD flat board of 0.5mg/mL G418 containing toward step (4) with aseptic toothpick, mixing is cultivated 48h in 30 ℃;
(6) after 48h, get new aseptic 96 orifice plates, every hole adds 190 μ L YPD liquid nutrient mediums.The culture that adds first 96 orifice plate gained of 10 μ L in respective aperture is cultivated 24h in 30 ℃;
(7) after 24h, then get new aseptic 96 orifice plates, every hole adds 190 μ L YPD liquid nutrient mediums.The culture that adds second 96 orifice plate gained of 10 μ L in respective aperture is cultivated 24h in 30 ℃;
(8) after 24h, take out respectively 1 μ L and put respectively on the YPD flat board that contains 1.0mg/mL and 4.0mg/mL G418 from the 3rd 96 orifice plates, continue to cultivate 96h-120h in 30 ℃.If yeast SMD1168 transformant can be grown containing on the substratum of high density G418 more, illustrate that this transformant contains the more goal gene of multiple copied, namely have a plurality of pPIC9K-COL3-COL3-6His segments transform into yeast SMD1168 and homologous recombination inserted on the karyomit(e) of yeast.
3. preparation gene recombination human collagen
(1) cultivated pichia yeast genetic engineering bacteria 16 ~ 18 hours based on 30 ℃/250rpm, OD with the BMGY cultivation 600=2~6;
(2) the centrifugal 5min of 1500g~3000g under room temperature collects thalline, with the resuspended thalline of BMMY substratum, makes OD 600=1.0 left and right are placed in gained bacterium liquid the triangular flask of 500mL, with the double gauze sealing, in 30 ℃ of 250rpm continued growths;
(3) adding methyl alcohol to final concentration in every 24 hours in the substratum is 1% beginning inducing culture, until more than 100 hours;
(4) after fermentation culture finished, 4 ℃ of centrifugal 20min of lower 3000g collected supernatant;
(5) add the pure water of 5~7 times of volumes in supernatant, then through ultrafiltration and concentration to 20% of original volume;
(6) get and add 100 μ L 1 * Ni-NTA binding buffer liquid in the 1mL concentrated solution, 4 ℃ are fully mixed;
(7) add 4 ℃ of soft mixings of 20 μ L 50% Ni – NTA HisBind resin suspensions, in conjunction with 30 minutes;
(8) the centrifugal 10s precipitation of 15,000g resins are abandoned supernatant;
(9) with 100 μ L 1 * Ni-NTA rinsing damping fluid rinsing resins, centrifugal 10 seconds of 15,000g carefully sucks supernatant.Repeat again 1 time;
(10) with 20 μ L 1 * Ni-NTA elution buffer wash-out target proteins, centrifugal 10 seconds of 15,000 g carefully are transferred to supernatant in clean tubule.Repeat again 3 times.The supernatant that takes a morsel carries out the SDS-PAGE analyzing and testing;
(11) collect supernatant, add the pure water of 5 times of volumes, then through ultrafiltration and concentration to 10~20% of original volume;
(12) get the 10ml concentrated solution and pour in the 50ml small beaker, put into-20 ℃ of refrigerator freezings and spend the night, then change in freeze drier-45 ℃ over to, open vacuum pump, kept 48 hours;
(13) after freeze-drying finishes, carefully open purging valve, until inside and outside air pressure balance.Take out beaker, obtain the white powder gene recombination human collagen.
Embodiment 2
Now provide the embodiment that gene recombination human collagen is used for external application beauty and skin care product:
By following quality proportioning, with each raw material of water dissolution, and stir the transparent preserving moisture and protecting skin essence of a colorless and odorless:
Gene recombination human collagen 1%
Hyaluronate sodium 0.1%
Beta-glucan 1%
Jojoba ester 0.5%
Serine 0.1%
Sorbyl alcohol 5%
Trimethyl-glycine 5%
Sodium.alpha.-hydroxypropionate 3%
Using method: sooner or later after clean, directly be applied in face, chucked is to absorbing fully.
Embodiment 3:
By following quality proportioning, with each raw material of water dissolution, and stir the transparent preserving moisture and protecting skin essence of a colorless and odorless:
Gene recombination human collagen 0.01%
Hyaluronate sodium 0.01%
Beta-glucan 0.01%
Jojoba ester 0.01%
Serine 0.01%
Sorbyl alcohol 1%
Trimethyl-glycine 1%
Sodium.alpha.-hydroxypropionate 0.1%
Using method: sooner or later after clean, directly be applied in face, chucked is to absorbing fully.
Embodiment 4
Now provide the Application Example of gene recombination human collagen in high-grade Wicresoft cosmetics:
(1) accurately take gene recombination human collagen lyophilized powder 10.0mg, be dissolved in 5% mannitol solution, fully be settled to 10.0mL after dissolving;
(2) with 0.22 μ m micro emulsion membrane filtration degerming;
(3) under aseptic condition, every 1.0mL packing pours in the aseptic cillin bottle of 3mL, partly covers aseptic plug, after vacuum lyophilization, rolls aluminium lid, makes gene recombination human collagen and imports lyophilized powder;
(4) separately prepare 0.05% sodium hyaluronate solution, according to the method filtration sterilization of (2);
(5) be filled under aseptic condition in the aseptic cillin bottle of 3mL, every bottle of 3.0mL adds a cover aseptic plug, rolls aluminium lid, makes the lyophilized powder solvent;
When (6) using, with the whole solvents of disposable sterilized injector extraction, inject the freeze-drying powder bottle, shake up and make abundant dissolving, and then the cooperation of extraction solution imports the instrument use.
Embodiment 5
Now provide the acute oral toxicity test embodiment that gene recombination human collagen carries out as cosmetic material:
Laboratory animal: 20 healthy mices, 8~12 ages in week, male and female half and half, body weight 25~30 grams;
Raising condition: full nutrition granulated feed feeding, sub-cage rearing, 23 ± 3 ℃ of room temperatures, relative humidity 40 ~ 70%, illumination every day 12 hours, free tap water and searching for food.Before test, animal needs to adapt to 3 days in experimental situation;
Dosage: during prerun, do not find that sample 5000mg/kg body weight dosage has overt toxicity reaction and dead, therefore test is to greatest extent adopted once in formal experiment, dosage is made as the 5000mg/kg body weight;
Preparation: accurately take sample 3.0 grams, be dissolved in pure water, be settled to 30mL, be mixed with 10% concentration, as test liquid.
Testing sequence
Contaminating mode: give testing liquid by the amount of 0.2mL/10g body weight minute three per os gavages in 24 hours, front 12 hours of gavage is freely drunk water, and after gavage, fasting is 3~4 hours, but normal diet then;
Observe time limit and index: observed 14 days, and recorded animal toxicity symptom and death condition every day, in the observation period, surviving animals is weighed weekly, and after the observation period finishes, surviving animals is weighed, and LD is calculated in postmortem after putting to death 50
Test result: after gavage, all animal subjects have no obvious toxicity symptom and death within the observation period.Therefore its mouse oral toxicity LD 50The 5000mg/kg body weight.
Tested material is to its mouse oral toxicity test result
Dosage (mg/kg) Laboratory animal number (only) Dead animal number (only) Mortality ratio
5000 20 0 0.0
Conclusion: according to the acute oral toxicity evaluation regulation of " cosmetics health standard " (version in 2007), the nontoxic level in the true border of gene recombination human collagen sample.
Embodiment 6
Now provide the acute dermal toxicity experimental example that gene recombination human collagen carries out as cosmetic material:
Laboratory animal: 10 healthy rats, 8~12 ages in week, male and female half and half, body weight 200~250 grams;
Raising condition: full nutrition granulated feed feeding, sub-cage rearing, 23 ± 3 ℃ of room temperatures, relative humidity 40 ~ 70%, illumination every day 12 hours, free tap water and searching for food.Before test, animal needs to adapt to 3 days in experimental situation;
Dosage: during prerun, do not find that sample 2500mg/kg body weight dosage has overt toxicity reaction and dead, therefore test is to greatest extent adopted once in formal experiment, dosage is made as the 2500mg/kg body weight;
Preparation: by every the weight of animals weighing given the test agent, add several pure water furnishing pasty states.
Testing sequence
Contaminating mode: tested front 24 hours, with the back part of animal unhairing, area is about 40cm 2, given the test agent evenly is applied in the unhairing district, cover with gauze and oilpaper, then fix with medical proof fabric.Contaminate after 24 hours, remove, and clean residual sample on skin with warm water;
Observe time limit and index: observed 14 days, and recorded animal toxicity symptom and death condition every day, in the observation period, surviving animals is weighed weekly, and after the observation period finishes, surviving animals is weighed, and LD is calculated in postmortem after putting to death 50
Test result: all animal subjects have no obvious toxicity symptom and death within the observation period.Therefore rat percutaneous toxicity LD 50The 2500mg/kg body weight.
Tested material is to rat oral skin toxicity test result
Dosage (mg/kg) Laboratory animal number (only) Dead animal number (only) Mortality ratio
2500 10 0 0.0
Conclusion: according to the acute dermal toxicity evaluation regulation of " cosmetics health standard " (version in 2007), the nontoxic level in the true border of gene recombination human collagen sample.
SEQUENCE LISTING
<110〉the glad bio tech ltd of Xi'an benefit power
<120〉gene recombination human collagen
<130> ELG33H6
<160> 9
<170> PatentIn version 3.5
<210> 1
<211> 474
<212> PRT
<213〉artificial sequence
<220>
<221> SIMILAR
<222> (1)..(229)
<223〉human III type collagen segment
<220>
<221> CHAIN
<222> (1)..(474)
<223〉gene recombination human collagen complete sequence
<220>
<221> SIMILAR
<222> (233)..(461)
<223〉human III type collagen segment
<220>
<221> DOMAIN
<222> (462)..(474)
<223〉the modification fragment of C-terminal
<220>
<221> DOMAIN
<222> (463)..(468)
<223〉6His fragment
<400> 1
Ala Gly Asn Thr Gly Ala Pro Gly Ser Pro Gly Val Ser Gly Pro Lys
1 5   10  15
Gly Asp Ala Gly Gln Pro Gly Glu Lys Gly Ser Pro Gly Ala Gln Gly
  20    25    30
Pro Pro Gly Ala Pro Gly Pro Leu Gly Ile Ala Gly Ile Thr Gly Ala
 35    40    45
Arg Gly Leu Ala Gly Pro Pro Gly Met Pro Gly Pro Arg Gly Ser Pro
 50    55    60
Gly Pro Gln Gly Val Lys Gly Glu Ser Gly Lys Pro Gly Ala Asn Gly
65    70    75    80
Leu Ser Gly Glu Arg Gly Pro Pro Gly Pro Gln Gly Leu Pro Gly Leu
   85    90    95
Ala Gly Thr Ala Gly Glu Pro Gly Arg Asp Gly Asn Pro Gly Ser Asp
  100    105    110
Gly Leu Pro Gly Arg Asp Gly Ser Pro Gly Gly Lys Gly Asp Arg Gly
   115    120    125
Glu Asn Gly Ser Pro Gly Ala Pro Gly Ala Pro Gly His Pro Gly Pro
 130    135    140
Pro Gly Pro Val Gly Pro Ala Gly Lys Ser Gly Asp Arg Gly Glu Ser
145    150    155    160
Gly Pro Ala Gly Pro Ala Gly Ala Pro Gly Pro Ala Gly Ser Arg Gly
   165    170    175
Ala Pro Gly Pro Gln Gly Pro Arg Gly Asp Lys Gly Glu Thr Gly Glu
  180    185     190
Arg Gly Ala Ala Gly Ile Lys Gly His Arg Gly Phe Pro Gly Asn Pro
  195   200    205
Gly Ala Pro Gly Ser Pro Gly Pro Ala Gly Gln Gln Gly Ala Ile Gly
 210    215    220
Ser Pro Gly Pro Ala Glu Phe Thr Ala Gly Asn Thr Gly Ala Pro Gly
225    230    235    240
Ser Pro Gly Val Ser Gly Pro Lys Gly Asp Ala Gly Gln Pro Gly Glu
   245    250    255
Lys Gly Ser Pro Gly Ala Gln Gly Pro Pro Gly Ala Pro Gly Pro Leu
  260    265    270
Gly Ile Ala Gly Ile Thr Gly Ala Arg Gly Leu Ala Gly Pro Pro Gly
 275   280    285
Met Pro Gly Pro Arg Gly Ser Pro Gly Pro Gln Gly Val Lys Gly Glu
 290    295   300
Ser Gly Lys Pro Gly Ala Asn Gly Leu Ser Gly Glu Arg Gly Pro Pro
305    310    315    320
Gly Pro Gln Gly Leu Pro Gly Leu Ala Gly Thr Ala Gly Glu Pro Gly
   325    330    335
Arg Asp Gly Asn Pro Gly Ser Asp Gly Leu Pro Gly Arg Asp Gly Ser
  340    345    350
Pro Gly Gly Lys Gly Asp Arg Gly Glu Asn Gly Ser Pro Gly Ala Pro
 355    360    365
Gly Ala Pro Gly His Pro Gly Pro Pro Gly Pro Val Gly Pro Ala Gly
 370    375    380
Lys Ser Gly Asp Arg Gly Glu Ser Gly Pro Ala Gly Pro Ala Gly Ala
385    390    395    400
Pro Gly Pro Ala Gly Ser Arg Gly Ala Pro Gly Pro Gln Gly Pro Arg
   405    410    415
Gly Asp Lys Gly Glu Thr Gly Glu Arg Gly Ala Ala Gly Ile Lys Gly
  420    425    430
His Arg Gly Phe Pro Gly Asn Pro Gly Ala Pro Gly Ser Pro Gly Pro
 435    440    445
Ala Gly Gln Gln Gly Ala Ile Gly Ser Pro Gly Pro Ala Asp His His
 450    455   460
His His His His Thr Gly Leu Ala Arg Phe
465   470
<210> 2
<211> 22
<212> DNA
<213> Homo sapiens
<400> 2
gaatctgtga atcatgccct ac 22
<210> 3
<211> 23
<212> DNA
<213> Homo sapiens
<400> 3
gaagtcataa tctcatcggt gtt 23
<210> 4
<211> 24
<212> DNA
<213> Homo sapiens
<400> 4
aggctgaagc tgcgggtaac actg 24
<210> 5
<211> 27
<212> DNA
<213> Homo sapiens
<400> 5
tctctcgaga aaagagaggc tgaagct 27
<210> 6
<211> 20
<212> DNA
<213> Homo sapiens
<400> 6
ttgaattctg caggtcctgg 20
<210> 7
<211> 29
<212> DNA
<213〉artificial sequence
<400> 7
cccgaattca ctgcgggtaa cactggtgc 29
<210> 8
<211> 46
<212> DNA
<213〉artificial sequence
<400> 8
aaaaccggtg tggtggtggt ggtggtgatc tgcaggtcct ggactg 46
<210> 9
<211> 1422
<212> DNA
<213〉artificial sequence
<220>
<221> CDS
<222> (1)..(1422)
<223〉gene recombination human collagen gene order
<400> 9
gcg ggt aac act ggt gct cct ggc agc cct gga gtg tct gga cca aaa 48
Ala Gly Asn Thr Gly Ala Pro Gly Ser Pro Gly Val Ser Gly Pro Lys
1    5    10    15
ggt gat gct ggc caa cca gga gag aag gga tcg cct ggt gcc cag ggc 96
Gly Asp Ala Gly Gln Pro Gly Glu Lys Gly Ser Pro Gly Ala Gln Gly
   20    25    30
cca cca gga gct cca ggc cca ctt ggg att gct ggg atc act gga gca 144
Pro Pro Gly Ala Pro Gly Pro Leu Gly Ile Ala Gly Ile Thr Gly Ala
  35    40   45
cgg ggt ctt gca gga cca cca ggc atg cca ggt cct agg gga agc cct 192
Arg Gly Leu Ala Gly Pro Pro Gly Met Pro Gly Pro Arg Gly Ser Pro
 50    55     60
ggc cct cag ggt gtc aag ggt gaa agt ggg aaa cca gga gct aac ggt 240
Gly Pro Gln Gly Val Lys Gly Glu Ser Gly Lys Pro Gly Ala Asn Gly
65    70    75    80
ctc agt gga gaa cgt ggt ccc cct gga ccc cag ggt ctt cct ggt ctg 288
Leu Ser Gly Glu Arg Gly Pro Pro Gly Pro Gln Gly Leu Pro Gly Leu
   85     90    95
gct ggt aca gct ggt gaa cct gga aga gat gga aac cct gga tca gat 336
Ala Gly Thr Ala Gly Glu Pro Gly Arg Asp Gly Asn Pro Gly Ser Asp
  100    105    110
ggt ctt cca ggc cga gat gga tct cct ggt ggc aag ggt gat cgt ggt 384
Gly Leu Pro Gly Arg Asp Gly Ser Pro Gly Gly Lys Gly Asp Arg Gly
  115    120   125
gaa aat ggc tct cct ggt gcc cct ggc gct cct ggt cat cca ggc cca 432
Glu Asn Gly Ser Pro Gly Ala Pro Gly Ala Pro Gly His Pro Gly Pro
 130    135    140
cct ggt cct gtc ggt cca gct gga aag agt ggt gac aga gga gaa agt 480
Pro Gly Pro Val Gly Pro Ala Gly Lys Ser Gly Asp Arg Gly Glu Ser
145   150    155    160
ggc cct gct ggc cct gct ggt gct ccc ggt cct gct ggt tcc cga ggt 528
Gly Pro Ala Gly Pro Ala Gly Ala Pro Gly Pro Ala Gly Ser Arg Gly
   165   170    175
gct cct ggt cct caa ggc cca cgt ggt gac aaa ggt gaa aca ggt gaa 576
Ala Pro Gly Pro Gln Gly Pro Arg Gly Asp Lys Gly Glu Thr Gly Glu
  180    185    190
cgt gga gct gct ggc atc aaa gga cat cga gga ttc cct ggt aat cca 624
Arg Gly Ala Ala Gly Ile Lys Gly His Arg Gly Phe Pro Gly Asn Pro
 195   200    205
ggt gcc cca ggt tct cca ggc cct gct ggt cag cag ggt gca atc ggc 672
Gly Ala Pro Gly Ser Pro Gly Pro Ala Gly Gln Gln Gly Ala Ile Gly
 210   215    220
agt cca gga cct gca gaa ttc act gcg ggt aac act ggt gct cct ggc 720
Ser Pro Gly Pro Ala Glu Phe Thr Ala Gly Asn Thr Gly Ala Pro Gly
225   230    235   240
agc cct gga gtg tct gga cca aaa ggt gat gct ggc caa cca gga gag 768
Ser Pro Gly Val Ser Gly Pro Lys Gly Asp Ala Gly Gln Pro Gly Glu
  245    250   255
aag gga tcg cct ggt gcc cag ggc cca cca gga gct cca ggc cca ctt 816
Lys Gly Ser Pro Gly Ala Gln Gly Pro Pro Gly Ala Pro Gly Pro Leu
  260   265    270
ggg att gct ggg atc act gga gca cgg ggt ctt gca gga cca cca ggc 864
Gly Ile Ala Gly Ile Thr Gly Ala Arg Gly Leu Ala Gly Pro Pro Gly
 275   280    285
atg cca ggt cct agg gga agc cct ggc cct cag ggt gtc aag ggt gaa 912
Met Pro Gly Pro Arg Gly Ser Pro Gly Pro Gln Gly Val Lys Gly Glu
 290   295    300
agt ggg aaa cca gga gct aac ggt ctc agt gga gaa cgt ggt ccc cct 960
Ser Gly Lys Pro Gly Ala Asn Gly Leu Ser Gly Glu Arg Gly Pro Pro
305    310    315    320
gga ccc cag ggt ctt cct ggt ctg gct ggt aca gct ggt gaa cct gga 1008
Gly Pro Gln Gly Leu Pro Gly Leu Ala Gly Thr Ala Gly Glu Pro Gly
   325    330    335
aga gat gga aac cct gga tca gat ggt ctt cca ggc cga gat gga tct 1056
Arg Asp Gly Asn Pro Gly Ser Asp Gly Leu Pro Gly Arg Asp Gly Ser
  340    345    350
cct ggt ggc aag ggt gat cgt ggt gaa aat ggc tct cct ggt gcc cct 1104
Pro Gly Gly Lys Gly Asp Arg Gly Glu Asn Gly Ser Pro Gly Ala Pro
  355    360    365
ggc gct cct ggt cat cca ggc cca cct ggt cct gtc ggt cca gct gga 1152
Gly Ala Pro Gly His Pro Gly Pro Pro Gly Pro Val Gly Pro Ala Gly
 370   375    380
aag agt ggt gac aga gga gaa agt ggc cct gct ggc cct gct ggt gct 1200
Lys Ser Gly Asp Arg Gly Glu Ser Gly Pro Ala Gly Pro Ala Gly Ala
385    390    395    400
ccc ggt cct gct ggt tcc cga ggt gct cct ggt cct caa ggc cca cgt 1248
Pro Gly Pro Ala Gly Ser Arg Gly Ala Pro Gly Pro Gln Gly Pro Arg
    405    410    415
ggt gac aaa ggt gaa aca ggt gaa cgt gga gct gct ggc atc aaa gga 1296
Gly Asp Lys Gly Glu Thr Gly Glu Arg Gly Ala Ala Gly Ile Lys Gly
  420    425    430
cat cga gga ttc cct ggt aat cca ggt gcc cca ggt tct cca ggc cct 1344
His Arg Gly Phe Pro Gly Asn Pro Gly Ala Pro Gly Ser Pro Gly Pro
  435    440     445
gct ggt cag cag ggt gca atc ggc agt cca gga cct gca gat cac cac 1392
Ala Gly Gln Gln Gly Ala Ile Gly Ser Pro Gly Pro Ala Asp His His
 450    455   460
cac cac cac cac acc ggt ctt gct aga ttc 1422
His His His His Thr Gly Leu Ala Arg Phe
465   470

Claims (11)

1. humanization gene recombination collagen protein, it is characterized in that sequence is as follows: 474 amino acid of albumen total length, wherein 1~229 and 233~461 is the identical former fragment of human III type glue protein, there is EFT to connect between two sections human III type collagen segments, adopts DHHHHHHTGLARF to modify after 233~461 the former fragment of human III type glue protein; Its aminoacid sequence is as follows: (SEQ ID NO.1)
AGNTGAPGSP GVSGPKGDAG QPGEKGSPGA QGPPGAPGPL GIAGITGARG 50 LAGPPGMPGP RGSPGPQGVK GESGKPGANG LSGERGPPGP QGLPGLAGTA 100 GEPGRDGNPG SDGLPGRDGS PGGKGDRGEN GSPGAPGAPG HPGPPGPVGP 150 AGKSGDRGES GPAGPAGAPG PAGSRGAPGP QGPRGDKGET GERGAAGIKG 200 HRGFPGNPGA PGSPGPAGQQ GAIGSPGPAE FTAGNTGAPG SPGVSGPKGD 250 AGQPGEKGSP GAQGPPGAPG PLGIAGITGA RGLAGPPGMP GPRGSPGPQG 300
VKGESGKPGA NGLSGERGPP GPQGLPGLAG TAGEPGRDGN PGSDGLPGRD 350 GSPGGKGDRG ENGSPGAPGA PGHPGPPGPV GPAGKSGDRG ESGPAGPAGA 400 PGPAGSRGAP GPQGPRGDKG ETGERGAAGI KGHRGFPGNP GAPGSPGPAG  450 QQGAIGSPGP ADHHHHHHTG LARF                    474。
2. engineering bacteria of producing the described albumen of claim 1 is characterized in that this project bacterium is obtained by following step:
(1) clone's human III type glue protein gene
Extract total RNA from people's fresh human placenta, reverse transcription is cDNA, according to GenBank III type human collagen COL3A1 gene order, and design gene PCR amplimer F, R:
(SEQ ID NO.2)F: GAATCTGTGAATCATGCCCTAC
(SEQ ID NO.3)R: GAAGTCATAATCTCATCGGTGTT
Amplification obtains gene fragment take cDNA as masterplate, and product length is 3295bp;
(2) build plasmid pPIC9K-COL3-COL3-6His
Utilize sepharose DNA to reclaim test kit, press product description, reclaim specific band COL3A1 from 1.5% common sepharose; According to pGM-T clone test kit specification sheets, COL3A1 is connected on the pGM-T carrier, obtain plasmid pGM-T-COL3A1; Take the pGM-T-COL3A1 plasmid as template ,Increase as primer carries out multiplex PCR take F1, F2, R, obtaining product C OL3 length is 722bp, and primer is:
(SEQ ID NO.4)F1:AGGCTGAAGCTGCGGGTAACACTG
(SEQ ID NO.5)F2:TCTCTCGAGAAAAGAGAGGCTGAAGCT
(SEQ ID NO.6)R: TTGAATTCTGCAGGTCCTGG
Product C OL3 and plasmid pPIC9K are done respectively EcoR I, Xho I double digestion, and be connected to become plasmid pPIC9K-COL3 through the T4 DNA ligase;
Take plasmid pPIC9K-COL3 as template, the COL3 that again increases obtains COL3-6His, and primer is:
F:CCCGAATTCACTGCGGGTAACACTGGTGC (SEQ ID NO.7)
R:AAAACCGGTGTGGTGGTGGTGGTGGTGATCTGCAGGTCCTGGACTG(SEQ ID NO.8)
Secondary amplified production COL3-6His and plasmid pPIC9K-COL3 are carried out respectively EcoRI, AgeI double digestion, and be connected to become plasmid pPIC9K-COL3-COL3-6His through the T4 DNA ligase;
(3) pichia yeast genetic engineering bacteria of gene recombination construction expression human III type glue protein
With the plasmid pPIC9K-COL3-COL3-6His restriction enzyme for preparing SalI linearizing, and preparation pichia spp SMD1168(Invitrogen) competent cell, electric shock transforms the pPIC9K-COL3-COL3-6His plasmid, selects high copy positive colony with the G418 gradient method, obtains pichia yeast genetic engineering bacteria.
3. the method for preparing the described albumen of claim 1 is characterized in that cultivating based on 30 ℃ of 250rpm with BMGY and cultivated pichia yeast genetic engineering bacteria claimed in claim 2 16 ~ 18 hours, to OD 600=2~6; The centrifugal 5min of 1500g~3000g under room temperature collects thalline, with the resuspended thalline of BMMY substratum, makes OD 600=1.0 left and right are placed in triangular flask with the bacterium liquid of gained, with the double gauze sealing, in 30 ℃ of 250rpm continued growths; Adding methyl alcohol to final concentration in every 24 hours in the substratum is 1% beginning inducing culture, until more than 100 hours; After fermentation culture finishes, centrifugal collection supernatant, with Ni-NTA His Bands resin (Merck) absorption recombinant collagen, rinse streams goes out impurity under non-Denaturing, and wash-out recombinant collagen again, collect elutriant at last; Elutriant is through ultrafiltration system (PALL) desalination, concentrated, concentrated solution obtained by freeze drying gene recombination human collagen.
4. the gene order of the described albumen of claim 1 of encoding, is characterized in that sequence is as follows: (SEQ ID NO.9)
1 GCGGGTAACA CTGGTGCTCC TGGCAGCCCT GGAGTGTCTG GACCAAAAGG
51 TGATGCTGGC CAACCAGGAG AGAAGGGATC GCCTGGTGCC CAGGGCCCAC
101 CAGGAGCTCC AGGCCCACTT GGGATTGCTG GGATCACTGG AGCACGGGGT
151 CTTGCAGGAC CACCAGGCAT GCCAGGTCCT AGGGGAAGCC CTGGCCCTCA
201 GGGTGTCAAG GGTGAAAGTG GGAAACCAGG AGCTAACGGT CTCAGTGGAG
251 AACGTGGTCC CCCTGGACCC CAGGGTCTTC CTGGTCTGGC TGGTACAGCT
301 GGTGAACCTG GAAGAGATGG AAACCCTGGA TCAGATGGTC TTCCAGGCCG
351 AGATGGATCT CCTGGTGGCA AGGGTGATCG TGGTGAAAAT GGCTCTCCTG
401 GTGCCCCTGG CGCTCCTGGT CATCCAGGCC CACCTGGTCC TGTCGGTCCA
451 GCTGGAAAGA GTGGTGACAG AGGAGAAAGT GGCCCTGCTG GCCCTGCTGG
501 TGCTCCCGGT CCTGCTGGTT CCCGAGGTGC TCCTGGTCCT CAAGGCCCAC
551 GTGGTGACAA AGGTGAAACA GGTGAACGTG GAGCTGCTGG CATCAAAGGA
601 CATCGAGGAT TCCCTGGTAA TCCAGGTGCC CCAGGTTCTC CAGGCCCTGC
651 TGGTCAGCAG GGTGCAATCG GCAGTCCAGG ACCTGCAGAA TTCACTGCGG
701 GTAACACTGG TGCTCCTGGC AGCCCTGGAG TGTCTGGACC AAAAGGTGAT
751 GCTGGCCAAC CAGGAGAGAA GGGATCGCCT GGTGCCCAGG GCCCACCAGG
801 AGCTCCAGGC CCACTTGGGA TTGCTGGGAT CACTGGAGCA CGGGGTCTTG
851 CAGGACCACC AGGCATGCCA GGTCCTAGGG GAAGCCCTGG CCCTCAGGGT
901 GTCAAGGGTG AAAGTGGGAA ACCAGGAGCT AACGGTCTCA GTGGAGAACG
951 TGGTCCCCCT GGACCCCAGG GTCTTCCTGG TCTGGCTGGT ACAGCTGGTG
1001 AACCTGGAAG AGATGGAAAC CCTGGATCAG ATGGTCTTCC AGGCCGAGAT
1051 GGATCTCCTG GTGGCAAGGG TGATCGTGGT GAAAATGGCT CTCCTGGTGC
1101 CCCTGGCGCT CCTGGTCATC CAGGCCCACC TGGTCCTGTC GGTCCAGCTG
1151 GAAAGAGTGG TGACAGAGGA GAAAGTGGCC CTGCTGGCCC TGCTGGTGCT
1201 CCCGGTCCTG CTGGTTCCCG AGGTGCTCCT GGTCCTCAAG GCCCACGTGG
1251 TGACAAAGGT GAAACAGGTG AACGTGGAGC TGCTGGCATC AAAGGACATC
1301 GAGGATTCCC TGGTAATCCA GGTGCCCCAG GTTCTCCAGG CCCTGCTGGT
1351 CAGCAGGGTG CAATCGGCAG TCCAGGACCT GCAGATCACC ACCACCACCA
1401 CCACACCGGT CTTGCTAGAT TC。
5. recombined collagen purification process when be used for using gene recombination engineering bacteria Restruction people derived collagen albumen, it is characterized in that in carrying out gene recombination engineering bacteria building process, when carrying out recombination human source collagen, amino acid sequences Design, use is accompanied with the nucleotide primer of protein modification function, adopt the mode of additional DHHHHHHTGLARF to modify to people's derived collagen Argine Monohydrochloride sequence, and pass through the mode purifying of Ni – NTA HisBind resin absorption when extracting the recombination human source collagen protein from engineering bacterium fermentation liquid.
6. one kind is used for claimed in claim 5ly, is accompanied with the nucleotide primer of protein modification function, when it is characterized in that according to people's derived collagen Argine Monohydrochloride sequences Design nucleotide primer, increases by 6 nucleotide sequences that are used for expressing Histidine of design at the C end.
7. being used for according to claim 6 increasing by 6 nucleotide sequences that are used for the expression Histidine at the C end is GTGGTGGTGGTGGTGGTG.
8. the nucleotide primer that is accompanied with the protein modification function claimed in claim 6 is characterized in that its nucleotides sequence classifies as
F:CCCGAATTCACTGCGGGTAACACTGGTGC
R:AAAACCGGTGTGGTGGTGGTGGTGGTGATCTGCAGGTCCTGGACTG 。
9. gene recombination human collagen claimed in claim 1 is in the purposes of preparation in makeup.
10. an external-use skin care product that is used for beauty treatment, is characterized in that prepared product take water as solvent, is comprised of the raw material of following quality proportioning:
Gene recombination human collagen 0.01~1%
Hyaluronate sodium 0.01~0.1%
Beta-glucan 0.01~1%
Jojoba ester 0.01~0.5%
Serine 0.01~1%
Sorbyl alcohol 1~5%
Trimethyl-glycine 1~5%
Sodium.alpha.-hydroxypropionate 0.1~3%.
11. an importing product that is used for beauty treatment is characterized in that respectively by lyophilized powder and solvent composition, lyophilized powder is formed by the aseptic preparation of raw material of following quality proportioning, and lyophilize:
Gene recombination human collagen 0.1%
N.F,USP MANNITOL 5%;
Solvent is comprised of 0.05% aseptic sodium hyaluronate solution.
CN201310033299.6A 2013-01-29 2013-01-29 Genetic recombinant human-like collagen Active CN103102407B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310033299.6A CN103102407B (en) 2013-01-29 2013-01-29 Genetic recombinant human-like collagen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310033299.6A CN103102407B (en) 2013-01-29 2013-01-29 Genetic recombinant human-like collagen

Publications (2)

Publication Number Publication Date
CN103102407A true CN103102407A (en) 2013-05-15
CN103102407B CN103102407B (en) 2014-04-30

Family

ID=48310632

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310033299.6A Active CN103102407B (en) 2013-01-29 2013-01-29 Genetic recombinant human-like collagen

Country Status (1)

Country Link
CN (1) CN103102407B (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103550071A (en) * 2013-11-14 2014-02-05 陕西东大生化科技有限责任公司 Anti-ageing gene oligopeptide-containing preparation and application of preparation to cosmetics
CN106256911A (en) * 2016-07-22 2016-12-28 江苏江山聚源生物技术有限公司 A kind of Pichia sp. fermentation medium being applicable to large-scale production recombination human source collagen protein
CN106520869A (en) * 2016-12-07 2017-03-22 成都远睿生物技术有限公司 Fermentation method and fermentation medium for recombinant human III type collagen engineering bacteria
CN107090458A (en) * 2017-06-29 2017-08-25 江苏悦智生物医药有限公司 Yeast recombined collagen
CN107753389A (en) * 2016-11-30 2018-03-06 江苏创铭医疗器械有限公司 A kind of recombined collagen foaming pectin facial mask and preparation method thereof
CN109529104A (en) * 2019-01-21 2019-03-29 创復(常州)生物科技有限公司 Promote gel dressing of cell Proliferation migration and preparation method thereof, application method
CN110606896A (en) * 2019-01-29 2019-12-24 江苏悦智生物医药有限公司 Recombinant human III-type collagen alpha 1 chain and application thereof
CN110747198A (en) * 2019-01-30 2020-02-04 江苏悦智生物医药有限公司 Method for producing recombinant human type-II collagen single chain by pichia pastoris
CN110960443A (en) * 2019-12-26 2020-04-07 广州领衔生物科技有限公司 Composition containing recombinant human collagen, freeze-dried material, preparation method of freeze-dried material and cosmetic
WO2021082391A1 (en) * 2019-10-30 2021-05-06 诺斯贝尔化妆品股份有限公司 Collagen nano instant facial mask of yeast recombinant collagen and preparation method therefor
CN113925959A (en) * 2021-11-19 2022-01-14 左立 Recombinant human collagen composition and application thereof
CN114276435A (en) * 2021-12-29 2022-04-05 广州赛莱拉干细胞科技股份有限公司 Recombinant human III-type collagen and application thereof
CN114632022A (en) * 2022-03-17 2022-06-17 山西锦波生物医药股份有限公司 Collagen freeze-dried fiber and preparation method and application thereof
CN114805548A (en) * 2021-12-29 2022-07-29 江苏创健医疗科技有限公司 Recombinant collagen freeze-dried fiber and preparation method thereof
CN115844024A (en) * 2022-10-12 2023-03-28 浙江诸暨聚源生物技术有限公司 Application of recombinant humanized collagen in preparation of edible anti-aging moisturizing and whitening products
CN116082493A (en) * 2022-08-10 2023-05-09 江苏创健医疗科技股份有限公司 High stability recombinant collagen, construction method and application thereof
JP2023521531A (en) * 2021-05-13 2023-05-25 江蘇創健医療科技有限公司 Recombinant human collagen type XVII, method of preparation and use
CN116286914A (en) * 2023-03-17 2023-06-23 南京斯拜科生物科技股份有限公司 Transmembrane protein complex gene and application thereof in biological fermentation preparation of recombinant human-like collagen
CN116987179A (en) * 2023-09-20 2023-11-03 英特菲尔(成都)生物制品有限责任公司 Long-acting heat-resistant collagen and preparation method and application thereof
JP2024115499A (en) * 2023-02-14 2024-08-26 広東丸美生物技術股▲フン▼有限公司 Recombinant collagen for skin soothing and repair and uses thereof
CN119708266A (en) * 2025-02-26 2025-03-28 首玺(广州)医疗科技有限责任公司 An insulin-like growth factor-1 linked polypeptide and its application in repairing endometrial damage

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115771A1 (en) * 2002-09-27 2004-06-17 Thomas Jefferson University Recombinant collagen-like proteins
CN102020716A (en) * 2010-10-29 2011-04-20 西安华澳丽康生物工程有限公司 Gene recombination human collagen fusion peptide segment, preparation method and application thereof
CN102349867A (en) * 2011-11-02 2012-02-15 广州舒泰生物技术有限公司 Water-replenishing repairing cosmetic as well as preparation method and application thereof
CN102675473A (en) * 2012-05-07 2012-09-19 西安华澳丽康生物工程有限公司 Gene recombinant human type active basic fibroblast growth factor fusion protein and its preparation method and application

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115771A1 (en) * 2002-09-27 2004-06-17 Thomas Jefferson University Recombinant collagen-like proteins
CN102020716A (en) * 2010-10-29 2011-04-20 西安华澳丽康生物工程有限公司 Gene recombination human collagen fusion peptide segment, preparation method and application thereof
CN102349867A (en) * 2011-11-02 2012-02-15 广州舒泰生物技术有限公司 Water-replenishing repairing cosmetic as well as preparation method and application thereof
CN102675473A (en) * 2012-05-07 2012-09-19 西安华澳丽康生物工程有限公司 Gene recombinant human type active basic fibroblast growth factor fusion protein and its preparation method and application

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103550071A (en) * 2013-11-14 2014-02-05 陕西东大生化科技有限责任公司 Anti-ageing gene oligopeptide-containing preparation and application of preparation to cosmetics
CN106256911A (en) * 2016-07-22 2016-12-28 江苏江山聚源生物技术有限公司 A kind of Pichia sp. fermentation medium being applicable to large-scale production recombination human source collagen protein
CN107753389A (en) * 2016-11-30 2018-03-06 江苏创铭医疗器械有限公司 A kind of recombined collagen foaming pectin facial mask and preparation method thereof
CN106520869A (en) * 2016-12-07 2017-03-22 成都远睿生物技术有限公司 Fermentation method and fermentation medium for recombinant human III type collagen engineering bacteria
CN107090458A (en) * 2017-06-29 2017-08-25 江苏悦智生物医药有限公司 Yeast recombined collagen
CN109529104A (en) * 2019-01-21 2019-03-29 创復(常州)生物科技有限公司 Promote gel dressing of cell Proliferation migration and preparation method thereof, application method
CN110606896A (en) * 2019-01-29 2019-12-24 江苏悦智生物医药有限公司 Recombinant human III-type collagen alpha 1 chain and application thereof
CN110747198A (en) * 2019-01-30 2020-02-04 江苏悦智生物医药有限公司 Method for producing recombinant human type-II collagen single chain by pichia pastoris
CN110747198B (en) * 2019-01-30 2021-04-06 江苏创健医疗科技有限公司 Method for producing recombinant human type-II collagen single chain by pichia pastoris
JP2023500191A (en) * 2019-10-30 2023-01-05 ノックス ベルカウ コズメティックス カンパニー リミテッド Collagen nano instant face pack containing yeast recombinant collagen and method for producing the same
WO2021082391A1 (en) * 2019-10-30 2021-05-06 诺斯贝尔化妆品股份有限公司 Collagen nano instant facial mask of yeast recombinant collagen and preparation method therefor
CN110960443A (en) * 2019-12-26 2020-04-07 广州领衔生物科技有限公司 Composition containing recombinant human collagen, freeze-dried material, preparation method of freeze-dried material and cosmetic
JP7411858B2 (en) 2021-05-13 2024-01-12 江蘇創健医療科技股▲ふん▼有限公司 Recombinant human collagen type XVII, preparation method, and use
JP2023521531A (en) * 2021-05-13 2023-05-25 江蘇創健医療科技有限公司 Recombinant human collagen type XVII, method of preparation and use
CN113925959A (en) * 2021-11-19 2022-01-14 左立 Recombinant human collagen composition and application thereof
CN113925959B (en) * 2021-11-19 2023-11-07 左立 Recombinant human collagen composition and application thereof
CN114276435B (en) * 2021-12-29 2023-12-01 广州赛莱拉干细胞科技股份有限公司 Recombinant humanized III type collagen and application thereof
CN114276435A (en) * 2021-12-29 2022-04-05 广州赛莱拉干细胞科技股份有限公司 Recombinant human III-type collagen and application thereof
CN114805548A (en) * 2021-12-29 2022-07-29 江苏创健医疗科技有限公司 Recombinant collagen freeze-dried fiber and preparation method thereof
CN114805548B (en) * 2021-12-29 2023-11-14 江苏创健医疗科技股份有限公司 Recombinant collagen freeze-dried fiber and preparation method thereof
CN114632022A (en) * 2022-03-17 2022-06-17 山西锦波生物医药股份有限公司 Collagen freeze-dried fiber and preparation method and application thereof
CN116082493A (en) * 2022-08-10 2023-05-09 江苏创健医疗科技股份有限公司 High stability recombinant collagen, construction method and application thereof
WO2024032467A1 (en) * 2022-08-10 2024-02-15 江苏创健医疗科技股份有限公司 High-stability recombinant collagen, and construction method therefor and use thereof
CN116082493B (en) * 2022-08-10 2023-11-07 江苏创健医疗科技股份有限公司 Highly stable recombinant collagen, construction methods and applications
CN115844024A (en) * 2022-10-12 2023-03-28 浙江诸暨聚源生物技术有限公司 Application of recombinant humanized collagen in preparation of edible anti-aging moisturizing and whitening products
JP2024115499A (en) * 2023-02-14 2024-08-26 広東丸美生物技術股▲フン▼有限公司 Recombinant collagen for skin soothing and repair and uses thereof
JP7601957B2 (en) 2023-02-14 2024-12-17 広東丸美生物技術股▲フン▼有限公司 Recombinant collagen for skin soothing and repair and uses thereof
CN116286914B (en) * 2023-03-17 2024-04-16 南京斯拜科生物科技股份有限公司 Transmembrane protein complex gene and application thereof in biological fermentation preparation of recombinant human-like collagen
CN116286914A (en) * 2023-03-17 2023-06-23 南京斯拜科生物科技股份有限公司 Transmembrane protein complex gene and application thereof in biological fermentation preparation of recombinant human-like collagen
CN116987179B (en) * 2023-09-20 2023-12-12 英特菲尔(成都)生物制品有限责任公司 Collagen and preparation method and application thereof
CN116987179A (en) * 2023-09-20 2023-11-03 英特菲尔(成都)生物制品有限责任公司 Long-acting heat-resistant collagen and preparation method and application thereof
CN119708266A (en) * 2025-02-26 2025-03-28 首玺(广州)医疗科技有限责任公司 An insulin-like growth factor-1 linked polypeptide and its application in repairing endometrial damage
CN119708266B (en) * 2025-02-26 2025-06-06 首玺(广州)医疗科技有限责任公司 An insulin-like growth factor-1 linked polypeptide and its application in repairing endometrial damage

Also Published As

Publication number Publication date
CN103102407B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
CN103102407B (en) Genetic recombinant human-like collagen
CN104195205B (en) Method and prepared high activity collagen peptide and application thereof from animal placenta preparation high activity collagen peptide
CN1896268B (en) Method for extracting activated small molecule sheep placenta from sheep embryo and its use
CN102020716A (en) Gene recombination human collagen fusion peptide segment, preparation method and application thereof
CN101063161A (en) Coproduction technique for collagen and chondroitin sulfate
CN101580807A (en) Strain for generating keratinase and application thereof
CN106279439A (en) A kind of oligopeptide 1 fusion protein containing cell-penetrating peptide and preparation method thereof
CN108118077A (en) The technique that a kind of enzymatic hydrolysis salmon collagen prepares anti-oxidation peptide and antifreeze peptide
CN117771152B (en) Skin-tendering anti-wrinkle bifidobacterium longum SF-B-60 fermentation product and preparation method and application thereof
CN105238831A (en) Moringa seed micro-molecular peptide extracted from moringa seeds, and extraction method thereof
CN100402548C (en) Method for preparing physiological active polypeptide of deer placenta
CN115521371B (en) Recombinant humanized III type collagen, preparation method and application
CN105255985A (en) Crocodile small molecule peptide extracted from bone of crocodile and extraction method of crocodile small molecule peptide
Morse Factors involved in the atrophy of the organs of the larval frog
CN114164145B (en) Brevibacillus borstelensis, neutral protease and application thereof
Sakib Extraction of Collagen Through Fish Waste Fermentation Optimization and Its Cytotoxic Studies on HaCaT Cell Line
CN102875659A (en) Antibacterial peptide secreted by skins of northeast forest frog, and coding sequence and application thereof
CN100497370C (en) Bursopoietin extracting method and its use in disease treating and immune
BRPI0409023A (en) culture medium, method for preparing said medium, collection and cloning of stem cells, microaggregated water, composition and method for preparing it
US20210393501A1 (en) Preparation method and application of recombinant mutant collagenase
KR20120081454A (en) Manufacturing method of fermented collagen
CN106632606A (en) Antimicrobial lipopeptide bacaucin derivatives and application thereof in bacterial infection inhibition
US20220112267A1 (en) Produce and isolate and/or extract collagen and/or gelatin from animal cell lines and/or tissue explants
CN101307093B (en) Method for separating and purifying collagen for biopharmaceutical use from sharkskin
CN102993309A (en) Human auxin fusion protein TAT-hGH as well as preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: LIANG LIANG

Effective date: 20140324

Owner name: LI PENG

Free format text: FORMER OWNER: XI'AN ELAGEN BIOTECHNOLOGY CO., LTD.

Effective date: 20140324

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 710065 XI'AN, SHAANXI PROVINCE TO: 710018 XI'AN, SHAANXI PROVINCE

TA01 Transfer of patent application right

Effective date of registration: 20140324

Address after: Weiyang District of Fengcheng city of Xi'an province Shaanxi six road 710018 No. 151

Applicant after: Li Peng

Applicant after: Liang Liang

Address before: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an

Applicant before: XI'AN ELAGEN BIOLOGICAL TECHNOLOGY Co.,Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160325

Address after: 710018 Shaanxi province Xi'an Weiyang road Fengcheng nine birch Jucui Ming Park Room 22011

Patentee after: Liang Liang

Address before: Weiyang District of Fengcheng city of Xi'an province Shaanxi six road 710018 No. 151

Patentee before: Li Peng

Patentee before: Liang Liang

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160824

Address after: 213000 Jiangsu city of Changzhou province Wujin Jincheng Road Economic Development Zone No. 18

Patentee after: JIANGSU YUEZHI BIOLOGY MEDICINE CO.,LTD.

Address before: 710018 Shaanxi province Xi'an Weiyang road Fengcheng nine birch Jucui Ming Park Room 22011

Patentee before: Liang Liang

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 213000 No. 28 Shuanglong Road, Jintan District, Changzhou City, Jiangsu Province

Patentee after: Jiangsu Yuezhi Biotechnology Co.,Ltd.

Address before: No.18, Jincheng Road, Wujin economic development zone, Jiangsu Province, 213000

Patentee before: JIANGSU YUEZHI BIOLOGY MEDICINE Co.,Ltd.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 213000 No.28 Shuanglong Road, Jintan District, Changzhou City, Jiangsu Province

Patentee after: Jiangsu chuangjian Medical Technology Co.,Ltd.

Address before: 213000 No.28 Shuanglong Road, Jintan District, Changzhou City, Jiangsu Province

Patentee before: Jiangsu Yuezhi Biotechnology Co.,Ltd.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 213000 No.28 Shuanglong Road, Jintan District, Changzhou City, Jiangsu Province

Patentee after: Jiangsu Chuangjian Medical Technology Co.,Ltd.

Address before: 213000 No.28 Shuanglong Road, Jintan District, Changzhou City, Jiangsu Province

Patentee before: Jiangsu chuangjian Medical Technology Co.,Ltd.